Tobacco Use Disorder Clinical Trial
Official title:
CSP #519 - Integrating Practice Guidelines for Smoking Cessation Into Mental Health Care for PTSD (SCP)
The primary study objective is to conduct a prospective, randomized controlled clinical
trial that compares the effectiveness of two approaches for delivering smoking cessation
treatment for veterans with posttraumatic stress disorder (PTSD). An approach where smoking
cessation treatment is integrated into mental health care for PTSD and delivered by mental
health providers (experimental condition) will be compared to specialized smoking cessation
clinic referral (VA's usual standard of care).
Secondary study objectives are to (a) compare the cost outcomes and cost-effectiveness of IC
versus USC, (b) identify treatment process variables that explain (mediate) observed
differences in smoking abstinence rates for the two study conditions, and (c) determine
whether cessation from smoking is associated with worsening of symptoms of PTSD and/or
depression.
Intervention: The research will test the effectiveness of integrating evidence-based,
efficacious treatments for tobacco use disorder into mental health care for patients with
chronic PTSD. Two different methods for delivering smoking cessation treatment will be
compared in a randomized, controlled clinical effectiveness trial conducted at four
Department of Veterans Affairs (VA) medical centers. Smokers undergoing mental health care
for PTSD who want to quit smoking will be randomly assigned to either (1)
guideline-concordant smoking cessation treatment integrated within ongoing mental health
care for PTSD, and delivered by mental health providers (Integrated Care (IC), experimental
condition), or (2) specialized smoking cessation treatment, delivered separately from PTSD
treatment by a smoking cessation clinic (Usual Standard of Care (USC), comparison
condition).
Primary Hypothesis: IC will be more effective than USC on measures of smoking-related
clinical outcomes.
Secondary Hypothesis: The following treatment process variables will predict smoking
abstinence at 12-months post randomization: (a) number of smoking cessation treatment
sessions received, (b) type and duration of protocol medications prescribed by providers
(bupropion, transdermal nicotine patch, and nicotine gum), (c) degree of subjects'
compliance with prescribed protocol medication, and (d) number of quit attempts marked by
abstinence of 7 days or more.
Treatment process variables that predict smoking abstinence will be present to a
significantly greater degree in IC than USC.
Primary Outcomes: The primary outcome measure will be the point-prevalence of smoking
abstinence by self-report for the 7 days prior to assessments, obtained at months 3, 6, 9,
and 12 following randomization to study conditions. Verification of smoking abstinence will
be obtained by CO readings (abstinence < 10 ppm) obtained at each assessment interval.
Salivary cotinine levels (abstinence < 20 ng/ml) will be measured to verify abstinence at
months 9 and 12 only, as subjects may still be using nicotine replacement medicines at
earlier assessment intervals, confounding cotinine assays.
Study Abstract: Individuals with posttraumatic stress disorder (PTSD) are far more likely to
smoke than those without mental illness and they smoke more heavily. Tobacco use likely
contributes to the heightened overall mortality and specific risks for smoking related
diseases among veterans with PTSD and commonly co-occurring mental disorders.
Symptoms of PTSD and associated mental disorders are linked to the maintenance of tobacco
dependence, premature dropout from smoking cessation treatment, and relapse to smoking
following quit attempts. Many efficacious tobacco use treatments exist, but a number of
barriers limit the effectiveness of current methods for delivering these treatments in VA
health care settings, particularly for the mentally ill. Novel approaches to smoking
cessation for individuals with PTSD are needed to circumvent these barriers by integrating
evidence-based tobacco use treatment into ongoing mental health care. The research proposed
here will test the effectiveness of integrating evidence-based treatment for nicotine
dependence into mental health care for patients with chronic posttraumatic stress disorder
(PTSD). Two different methods for delivering smoking cessation treatment will be compared in
a prospective, randomized controlled clinical effectiveness trial conducted at four
Department of Veterans Affairs (VA) medical centers. Smokers undergoing mental health care
for PTSD (n=440) will be randomly assigned to either: (1) practice guideline-concordant
smoking cessation treatment that is integrated within ongoing mental health care for PTSD
and delivered by mental health providers (Integrated Care [IC]) or 2) smoking cessation
treatment delivered separately from PTSD treatment by smoking cessation specialists (Usual
Standard of Care [USC]). Specific aims of the proposed investigation are (1) to demonstrate
that IC is more effective than USC in reducing smoking in psychiatric patients with PTSD and
(2) to demonstrate that a number of treatment process variables, including the amount or
dose of intervention and patient-specific factors, predict abstinence from tobacco use in
smokers with PTSD. Intent-to-treat analyses and analyses for treatment completers will be
conducted, using a Generalized Estimating Equations approach. If the study hypothesis is
confirmed, system-wide implementation of the experimental intervention (IC) for veterans
with PTSD would double the number of patients who stop smoking compared to the usual
standard of care for tobacco use disorder. Study findings may have implications for
integrating smoking cessation treatment into mental health care for patients with disorders
other than PTSD.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02432066 -
Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions
|
Phase 2 | |
Completed |
NCT03960138 -
Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Completed |
NCT04646668 -
Comparative Abuse Liability Among African American and White Smokers
|
N/A | |
Completed |
NCT02560324 -
Effect of Ramelteon on Smoking Abstinence
|
Phase 2 | |
Completed |
NCT02347605 -
Medicinal Nicotine for Preventing Cue Induced Craving
|
N/A | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Terminated |
NCT01800500 -
Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers
|
N/A | |
Completed |
NCT01625767 -
Tobacco Approach Avoidance Training for Adolescent Smokers-1
|
Phase 2 | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Completed |
NCT01442753 -
Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth
|
N/A | |
Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
Completed |
NCT00967005 -
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
|
Phase 2 | |
Completed |
NCT01337817 -
A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers
|
Phase 1 | |
Active, not recruiting |
NCT00751660 -
Screening Methods in Finding Lung Cancer Early in Current or Former Smokers
|
N/A | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Completed |
NCT00664261 -
Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking
|
N/A | |
Completed |
NCT00158158 -
Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2
|
Phase 2/Phase 3 | |
Completed |
NCT00134927 -
A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches
|
N/A | |
Completed |
NCT01213524 -
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
|
Phase 2 |